ClinicalTrials.gg
RecruitingNCT07544628Updated Oct 7, 2026

A Phase 1 Study of Navlimetostat Tablet Formulations

A Phase 1 interventional study of Navlimetostat in Healthy Participants, sponsored by Bristol-Myers Squibb. Recruiting at 4 sites in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 7, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

This study aims to compare the PK of Navlimetostat after administration of a wet-granulation tablet versus the dry-granulation tablet formulation in healthy adult female

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy adult female
  • Individuals not of childbearing potential
  • Open label study
  • Clinical Research Unit
  • Phase 1
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be healthy adult INOCBP female with no findings on medical history, PE, VS, 12-lead ECGs, or clinical laboratory determinations, as assessed by the investigator.
  • Participants must have of 18.0 to 35.0 kg/m2.
  • Participants must have adequate laboratory test results for renal and hepatic function, as assessed by the investigator, defined as ≥ 90 mL/min/1.73m2 using the CKD-EPI equation (screening only), and total , ALP, GGT, , ALT ≤ 1.5 × .

Exclusion criteria

Exclusion Criteria:

  • Participant must not have any significant acute or chronic medical illness (in the assessment of the investigator).
  • Participant must not have current or recent GI disease: Any gastrointestinal disease within 3 months of study intervention administration that could possibly affect drug absorption, distribution, metabolism, and excretion (eg, bariatric procedure, history of pancreatitis, uncontrolled nausea or vomiting) in the opinion of the investigator.
  • Other protocol defined inclusion/exclusion criteria applies.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Treatment A

    Drug: Navlimetostat

  • Experimental
    Treatment B

    Drug: Navlimetostat

Interventions

  • Specified dose on specified days

    Also known as: BMS-986504

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Time frame: Up to Day 17

  2. Area under the concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]

    Time frame: Up to Day 17

  3. Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]

    Time frame: Up to Day 17

  4. Number of participants with Adverse Events (AE)

    Time frame: Up to approximately day 37

  5. Number of participants with Serious Adverse Events (AE)

    Time frame: Up to approximately day 37

  6. Number of participants with clinically significant changes in Physical Examinations (PE)

    Time frame: Up to Day 17

  7. Number of participants with clinically significant changes in vital signs (VS)

    Time frame: Up to Day 17

  8. Number of participants with clinically significant changes in 12-lead ECGs

    Time frame: Up to Day 17

  9. Number of participants with clinically significant changes in laboratory tests results

    Time frame: Up to Day 17

Secondary outcomes

  1. Time of maximum observed drug concentration (Tmax)

    Time frame: Up to Day 17

  2. Terminal elimination half-life (T-HALF)

    Time frame: Up to Day 17

  3. Apparent total body clearance (CLT/F)

    Time frame: Up to Day 17

  4. Apparent volume of distribution during the terminal phase (Vz/F)

    Time frame: Up to Day 17

  5. Mean residence time (MRT)

    Time frame: Up to Day 17

07

Study locations

1 of 4 sites recruiting
  • CenExel iResearch - Decatur
    Decatur, Georgia 30030, United States
    Recruiting
    • Kimball Johnson, Site 0002 · Contact404-537-1281
  • Local Institution - 0003
    Decatur, Georgia 30030, United States
    Withdrawn

    Not enrolling at this site.

  • Local Institution - 0001
    Austin, Texas 78744, United States
    Withdrawn

    Not enrolling at this site.

  • Local Institution - 0004
    Austin, Texas 78744, United States
    Not yet recruiting
    • Site 0004 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Aug 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 22, 2026
StartActual
Apr 27, 2026
Primary completionEst.
Nov 2, 2026was Aug 2026
CompletionEst.
Nov 2, 2026was Oct 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Nov 2, 2026
Oct 7, 2026
Study completion
Oct 15, 2026→Nov 2, 2026
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Primary completion Aug 31, 2026→Nov 2, 2026
    Study completion Oct 15, 2026→Nov 2, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07544628
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Apr 27, 2026
Primary completion
Nov 2, 2026 (estimated)
Completion
Nov 2, 2026 (estimated)
Last update
Oct 7, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navlimetostat

Start the discussion